Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 29.44 -2.00% -0.60
RYTM closed down 2.0 percent on Tuesday, February 19, 2019, on 47 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Up Up
See historical RYTM trend table...

Date Alert Name Type % Chg
Feb 19 Fell Below 200 DMA Bearish 0.00%
Feb 19 Stochastic Sell Signal Bearish 0.00%
Feb 19 Multiple of Ten Bearish Other 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 15 200 DMA Support Bullish -2.00%
Feb 15 Pocket Pivot Bullish Swing Setup -2.00%
Feb 15 Multiple of Ten Bullish Other -2.00%
Feb 15 Overbought Stochastic Strength -2.00%
Feb 14 200 DMA Support Bullish -0.91%
Feb 14 Narrow Range Bar Range Contraction -0.91%

Older signals for RYTM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Biopharmaceutical Medical Specialties Organ Systems Obesity Peptide Hormones Peptides Metabolic Disorders
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.23
52 Week Low 16.8
Average Volume 118,462
200-Day Moving Average 29.5814
50-Day Moving Average 27.8386
20-Day Moving Average 28.271
10-Day Moving Average 29.006
Average True Range 1.2142
ADX 16.05
+DI 26.6277
-DI 16.7434
Chandelier Exit (Long, 3 ATRs ) 26.9874
Chandelier Exit (Short, 3 ATRs ) 28.9026
Upper Bollinger Band 30.8245
Lower Bollinger Band 25.7175
Percent B (%b) 0.73
BandWidth 18.064448
MACD Line 0.4754
MACD Signal Line 0.2619
MACD Histogram 0.2136
Fundamentals Value
Market Cap 767.62 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -9.41
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.58
Resistance 3 (R3) 30.68 30.40 30.39
Resistance 2 (R2) 30.40 30.11 30.35 30.33
Resistance 1 (R1) 29.92 29.93 29.78 29.82 30.26
Pivot Point 29.64 29.64 29.57 29.59 29.64
Support 1 (S1) 29.16 29.35 29.02 29.06 28.62
Support 2 (S2) 28.88 29.17 28.83 28.55
Support 3 (S3) 28.40 28.88 28.49
Support 4 (S4) 28.30